Home›Compare›FeelGood vs JRNYS

FeelGood vs JRNYS: Which Is Better?

Head-to-head comparison of FeelGood and JRNYS based on our independent scoring across trust, value, experience, product range, and reputation — plus real pricing for the treatments they both offer.

Our Verdict

JRNYS scores higher overall in our independent evaluation (62.8/100 vs 61/100), leading on trust & safety, experience, product range, reputation. FeelGood comes out ahead on value. FeelGood has the lower entry price (from $75/mo vs $89/mo), so the better value depends on which treatment you need.

61

FeelGood is a 2026-launched, OpenLoop-powered GLP-1 brand whose promotional page offers compounded semaglutide from $89/mo and tirzepatide from $149/mo with no membership fee, alongside ED and 'longevity' microdose tirzepatide programs.

Visit FeelGood
63
JRNYS
Fair

JRNYS is an Austin-based, physician-founded weight-loss membership. It prescribes branded and compounded GLP-1s, sexual-health drugs and NAD+/glutathione, with tiered coaching memberships from $89 to $169/mo.

Visit JRNYS

Score Breakdown

DimensionFeelGoodJRNYS
Overall Score61/10062.8/100 ✓
Trust & Safety30%50/10064/100 ✓
Value25%80/100 ✓55/100
Experience20%65/10066/100 ✓
Product Range15%60/10072/100 ✓
Reputation10%40/10058/100 ✓

At a Glance

Founded20262022
HeadquartersSheridan, WYAustin, TX
Publicly tradedNoNo
Treatment categories43
Treatments listed37
Starting price$75/mo$89/mo

Pricing Where They Compete

Prices shown are based on our most recent research and may not reflect current pricing. Telehealth providers update their pricing frequently. Always verify pricing directly with the provider before purchasing.

CategoryFeelGoodJRNYS
Weight Loss / GLP-1$75–$149
Compounded Semaglutide (injectable)
$89–$169
Weight Loss Membership (Basic / Tier I / Tier II)
Sexual Health——
Longevity & Peptides—$149
Glutathione

FeelGood

+Promotional pricing is among the lowest tracked: compounded semaglutide $89/mo and tirzepatide $149/mo, with no membership fee and free shipping
+Clinical care is delivered through OpenLoop's established telehealth provider network
+Native iOS and Android apps plus 24/7 messaging support; HSA/FSA accepted
−Unsubstantiated marketing claims: '100,000+ patients' on a domain registered in February 2026, and a '2.4 years younger' epigenetic-age claim for microdose tirzepatide
−High-pressure sales tactics, including countdown timers, 'price increases soon' banners and 'only 9 spots left this month' prompts
−Prices vary across its own pages ($149 'starting' on the main site vs $89 on the offer page), so the price a patient gets depends on which landing page they arrive through
Read the full FeelGood review →

JRNYS

+Named physician founder and CMO (Dr. Henry Legere, Columbia MD, Harvard fellowship)
+Supports both insurance-covered branded GLP-1s and cash-pay compounded semaglutide/tirzepatide
+Coaching built into membership, with one-on-one sessions every six weeks (Tier I) or weekly (Tier II)
−Compounded GLP-1 prices are not published and are only quoted after the provider consult
−The $89–169/mo membership is billed on top of medication, pushing all-in cash-pay cost above flat-fee competitors
−BBB rating of C with 20 complaints closed in the past three years
Read the full JRNYS review →

FeelGood vs JRNYS — FAQ

Is FeelGood better than JRNYS?

▾

JRNYS scores higher overall in our independent evaluation (62.8/100 vs 61/100), leading on trust & safety, experience, product range, reputation. FeelGood comes out ahead on value. FeelGood has the lower entry price (from $75/mo vs $89/mo), so the better value depends on which treatment you need.

Is FeelGood or JRNYS cheaper?

▾

FeelGood has the lower starting price (from $75/mo vs $89/mo for JRNYS). Starting prices are for the cheapest treatment each offers — compare the specific treatment you need, and check what each price includes.

What do FeelGood and JRNYS both offer?

▾

Both platforms treat Weight Loss / GLP-1, Sexual Health, Longevity & Peptides. FeelGood covers 4 treatment categories total and JRNYS covers 3.

Still deciding?